Home / Market News / $AMGN
fiscal.ai Corporate Catalyst Impact 85/100 ● positive

Amgen Announces Positive Phase 3 Results for Dazodalibep in Sjögren's Disease

Nov 11, 2026, 8:02 PM UTC · Primary ticker $AMGN

Amgen announced positive Phase 3 results for dazodalibep in Sjögren's disease, meeting primary endpoints for systemic disease activity and symptoms. This is a significant development as there are currently no FDA-approved treatments for this condition, positioning Amgen for a potential new market entry.

Amgen announced that its Phase 3 OASIZ-301 study for dazodalibep in Sjögren's disease successfully met its primary endpoints, demonstrating clinically meaningful improvements. This is a crucial development because Sjögren's disease currently lacks any FDA-approved treatments, creating a significant unmet medical need. The positive results position Amgen to potentially capture a new market, offering a first-in-class treatment. This news is a strong positive catalyst for AMGN in the short to medium term, as it de-risks the drug's path to market and signals future revenue potential. For traders, the opportunity lies in the potential for AMGN's stock to appreciate as regulatory filings and eventual approval draw closer, while the key risk would be any unexpected setbacks in the regulatory process or competitive entries.

$AMGN positive Successful Phase 3 trial, potential new drug approval
$GSK neutral Competitor in autoimmune disease space, but not directly impacted by this specific drug
$LLY neutral Competitor in autoimmune disease space, but not directly impacted by this specific drug
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.